Institutional portfolio tracker
Explore Braidwell's latest validated 13F portfolio and Hallucination Yield AI forecasts for covered positions.
Disclosed long book
$2.59 billion
Long positions
86
Calls / puts
0 / 0
Top 5 concentration
19.3%
Longs with AI data
4 / 86
Average AI 1Y
+12.9%
Monitored between quarterly reports
Schedules 13D and 13G can reveal a significant ownership event after a quarter closes. They are shown as a separate event timeline and never folded back into the 2026-06-30 Form 13F portfolio.
The filing reports BRAIDWELL LP's beneficial ownership as of June 30, 2026: 460,753 shares or share-equivalents representing 3.9% of the reported class. It was filed on August 14, 2026.
Official SEC disclosure ↗The filing reports BRAIDWELL LP's beneficial ownership as of June 30, 2026: 700,000 shares or share-equivalents representing 9.3% of the reported class. It was filed on August 14, 2026.
Official SEC disclosure ↗The filing reports BRAIDWELL LP's beneficial ownership as of December 31, 2025: 470,000 shares or share-equivalents representing 5.5% of the reported class. It was filed on February 17, 2026.
Official SEC disclosure ↗The filing reports BRAIDWELL LP's beneficial ownership as of December 31, 2024: 2,393,815 shares or share-equivalents representing 2.5% of the reported class. It was filed on February 14, 2025.
Official SEC disclosure ↗13F filing comparison
2026-03-31 to 2026-06-30
Newly reported
27
No longer reported
29
Increased
20
Reduced
34
Present now and absent from the immediately preceding comparable filing.
| Position | Kind | Shares | Value |
|---|---|---|---|
ALPHATEC HLDGS INC ALPHATEC HLDGS INC | LONG | 69,121,000 | $66.2 million |
HUMANA INC HUMANA INC | LONG | 114,500 | $45.5 million |
MAZE THERAPEUTICS INC MAZE THERAPEUTICS INC | LONG | 1,140,040 | $34.0 million |
AVALO THERAPEUTICS INC AVALO THERAPEUTICS INC | LONG | 1,629,182 | $30.1 million |
ALAMAR BIOSCIENCES INC ALAMAR BIOSCIENCES INC | LONG | 1,083,983 | $29.4 million |
ORUKA THERAPEUTICS INC ORUKA THERAPEUTICS INC | LONG | 278,164 | $26.5 million |
AVALYN PHARMACEUTICALS INC AVALYN PHARMACEUTICALS INC | LONG | 801,395 | $26.4 million |
NEOGENOMICS INC NEOGENOMICS INC | LONG | 18,011,000 | $16.9 million |
IMMUNOCORE HLDGS PLC IMMUNOCORE HLDGS PLC | LONG | 521,327 | $16.6 million |
REPLIGEN CORP REPLIGEN CORP | LONG | 16,000,000 | $16.4 million |
OVID THERAPEUTICS INC OVID THERAPEUTICS INC | LONG | 5,919,464 | $15.9 million |
MANNKIND CORP MANNKIND CORP | LONG | 3,458,429 | $14.7 million |
UNIQURE NV UNIQURE NV | LONG | 301,652 | $13.9 million |
OCULIS HOLDING AG OCULIS HOLDING AG | LONG | 834,183 | $11.6 million |
SEAPORT THERAPEUTICS INC SEAPORT THERAPEUTICS INC | LONG | 500,000 | $10.9 million |
IMMUNIC INC IMMUNIC INC | LONG | 645,010 | $9.9 million |
QUEST DIAGNOSTICS INC QUEST DIAGNOSTICS INC | LONG | 43,200 | $9.2 million |
ADLAI NORTYE LTD ADLAI NORTYE LTD | LONG | 795,214 | $9.1 million |
TENAX THERAPEUTICS INC TENAX THERAPEUTICS INC | LONG | 584,412 | $8.5 million |
KARDIGAN INC KARDIGAN INC | LONG | 300,000 | $7.2 million |
AMANAT ACQUISITION CORP AMANAT ACQUISITION CORP | LONG | 700,000 | $7.1 million |
HEMAB THERAPEUTICS HLDGS INC HEMAB THERAPEUTICS HLDGS INC | LONG | 160,000 | $5.9 million |
GH RESEARCH PLC GH RESEARCH PLC | LONG | 207,240 | $5.6 million |
WAT WATERS CORP | LONG | 14,040 | $5.3 million |
RESEARCH ALLIANCE CORP III RESEARCH ALLIANCE CORP III | LONG | 400,000 | $4.3 million |
JATT II ACQUISITION CORP JATT II ACQUISITION CORP | LONG | 250,000 | $2.8 million |
CYCLERION THERAPEUTICS INC CYCLERION THERAPEUTICS INC | LONG | 156,890 | $531,857 |
Present in the prior comparable filing and absent from this one.
| Position | Kind | Prior shares | Prior value |
|---|---|---|---|
ALPHATEC HLDGS INC ALPHATEC HLDGS INC · NOTE 0.750% 3/1 | LONG | 61,621,000 | $63.4 million |
APOGEE THERAPEUTICS INC APOGEE THERAPEUTICS INC · COM | LONG | 478,667 | $40.3 million |
ARROWHEAD PHARMACEUTICALS IN ARROWHEAD PHARMACEUTICALS IN · NOTE 1/1 | LONG | 2,250,000 | $2.3 million |
BIOMARIN PHARMACEUTICAL INC BIOMARIN PHARMACEUTICAL INC · COM | LONG | 497,020 | $28.1 million |
CELCUITY INC CELCUITY INC · COM | LONG | 29,198 | $3.3 million |
CENTENE CORP DEL CENTENE CORP DEL · COM | LONG | 330,000 | $10.8 million |
CENTESSA PHARMACEUTICALS PLC CENTESSA PHARMACEUTICALS PLC · SPONSORED ADS | LONG | 1,986,768 | $78.9 million |
CG ONCOLOGY INC CG ONCOLOGY INC · COM | LONG | 984,783 | $66.7 million |
COMPASS THERAPEUTICS INC COMPASS THERAPEUTICS INC · COM | LONG | 1,965,106 | $10.4 million |
CVS HEALTH CORP CVS HEALTH CORP · COM | LONG | 290,700 | $20.9 million |
DENALI THERAPEUTICS INC DENALI THERAPEUTICS INC · COM | LONG | 296,324 | $5.7 million |
ENGENE HOLDINGS INC ENGENE HOLDINGS INC · COM | LONG | 2,456,870 | $16.7 million |
ESTABLISHMENT LABS HLDGS INC ESTABLISHMENT LABS HLDGS INC · COM | LONG | 463,600 | $26.3 million |
FULCRUM THERAPEUTICS INC FULCRUM THERAPEUTICS INC · COM | LONG | 3,134,922 | $24.0 million |
GRAIL INC GRAIL INC · COM | LONG | 142,755 | $7.4 million |
GUARDANT HEALTH INC GUARDANT HEALTH INC · DEBT 1.250% 2/1 | LONG | 60,954,000 | $102.6 million |
HARROW INC HARROW INC · COM | LONG | 156,419 | $5.5 million |
ILLUMINA INC ILLUMINA INC · COM | LONG | 229,215 | $28.3 million |
NEOGENOMICS INC NEOGENOMICS INC · NOTE 0.250% 1/1 | LONG | 100,381,000 | $91.8 million |
NUVALENT INC NUVALENT INC · COM | LONG | 700,429 | $71.8 million |
PENUMBRA INC PENUMBRA INC · COM | LONG | 105,352 | $34.6 million |
PRAXIS PRECISION MEDICINES I PRAXIS PRECISION MEDICINES I · COM NEW | LONG | 9,976 | $3.2 million |
REPLIGEN CORP REPLIGEN CORP · NOTE 1.000%12/1 | LONG | 101,000,000 | $98.7 million |
REVOLUTION MEDICINES INC REVOLUTION MEDICINES INC · COM | LONG | 84,900 | $8.3 million |
PERKINELMER INC PERKINELMER INC · COM | LONG | 48,400 | $4.2 million |
SOLENO THERAPEUTICS INC SOLENO THERAPEUTICS INC · COM | LONG | 959,259 | $32.1 million |
TARSUS PHARMACEUTICALS INC TARSUS PHARMACEUTICALS INC · COM | LONG | 265,715 | $18.6 million |
TG THERAPEUTICS INC TG THERAPEUTICS INC · COM | LONG | 358,800 | $11.9 million |
ZENAS BIOPHARMA INC ZENAS BIOPHARMA INC · NOTE 2.500% 4/0 | LONG | 13,000,000 | $13.5 million |
“No longer reported” means the position is absent from this comparable 13F filing. It does not prove the manager sold it: reporting thresholds, confidential treatment, corporate actions, or instrument changes can also explain the omission.
| Position | Kind | Shares | Value | Long weight | Quarter change | AI at filing · 1Y | AI now |
|---|---|---|---|---|---|---|---|
CAI CARIS LIFE SCIENCES INC · COM · 142152107 | LONG | 8,256,032 | $147.1 million | 5.7% | INCREASED | — | 1Y — 5Y — |
HINGE HEALTH INC HINGE HEALTH INC · CL A · 433313103 | LONG | 1,330,127 | $110.4 million | 4.3% | REDUCED | — | 1Y — 5Y — |
GLAUKOS CORP GLAUKOS CORP · COM · 377322102 | LONG | 591,927 | $82.7 million | 3.2% | REDUCED | — | 1Y — 5Y — |
EDGEWISE THERAPEUTICS INC EDGEWISE THERAPEUTICS INC · COM · 28036F105 | LONG | 1,996,965 | $81.1 million | 3.1% | REDUCED | — | 1Y — 5Y — |
SPYRE THERAPEUTICS INC SPYRE THERAPEUTICS INC · COM NEW · 00773J202 | LONG | 879,467 | $78.1 million | 3.0% | REDUCED | — | 1Y — 5Y — |
IRHYTHM HOLDINGS INC IRHYTHM HOLDINGS INC · COM · 450056106 | LONG | 654,262 | $77.8 million | 3.0% | INCREASED | — | 1Y — 5Y — |
NEOGENOMICS INC NEOGENOMICS INC · COM NEW · 64049M209 | LONG | 4,918,202 | $71.8 million | 2.8% | REDUCED | — | 1Y — 5Y — |
KODIAK SCIENCES INC KODIAK SCIENCES INC · COM · 50015M109 | LONG | 1,787,318 | $69.6 million | 2.7% | REDUCED | — | 1Y — 5Y — |
XENON PHARMACEUTICALS INC XENON PHARMACEUTICALS INC · COM · 98420N105 | LONG | 1,131,452 | $68.3 million | 2.6% | REDUCED | — | 1Y — 5Y — |
ALPHATEC HLDGS INC ALPHATEC HLDGS INC · NOTE 0.750% 3/1 · 02081GAD4 | LONG | 69,121,000 | $66.2 million | — | NEWLY REPORTED | — | 1Y — 5Y — |
MONTE ROSA THERAPEUTICS INC MONTE ROSA THERAPEUTICS INC · COM · 61225M102 | LONG | 2,451,562 | $59.3 million | 2.3% | REDUCED | — | 1Y — 5Y — |
DIANTHUS THERAPEUTICS INC DIANTHUS THERAPEUTICS INC · COM · 252828108 | LONG | 594,562 | $58.0 million | 2.2% | REDUCED | — | 1Y — 5Y — |
NEUROCRINE BIOSCIENCES INC NEUROCRINE BIOSCIENCES INC · COM · 64125C109 | LONG | 336,171 | $56.7 million | 2.2% | REDUCED | — | 1Y — 5Y — |
ALPHATEC HLDGS INC ALPHATEC HLDGS INC · COM NEW · 02081G201 | LONG | 6,531,439 | $56.5 million | 2.2% | INCREASED | — | 1Y — 5Y — |
GENERATE BIOMEDICINES INC GENERATE BIOMEDICINES INC · COM SHS · 370920100 | LONG | 3,283,844 | $55.4 million | 2.1% | REDUCED | — | 1Y — 5Y — |
MARAVAI LIFESCIENCES HLDGS I MARAVAI LIFESCIENCES HLDGS I · COM CL A · 56600D107 | LONG | 8,702,921 | $54.3 million | 2.1% | REDUCED | — | 1Y — 5Y — |
KRYSTAL BIOTECH INC KRYSTAL BIOTECH INC · COM · 501147102 | LONG | 128,975 | $47.9 million | 1.9% | REDUCED | — | 1Y — 5Y — |
HUMANA INC HUMANA INC · COM · 444859102 | LONG | 114,500 | $45.5 million | 1.8% | NEWLY REPORTED | — | 1Y — 5Y — |
TMO Thermo Fisher Scientific Inc. | LONG | 89,395 | $44.8 million | 1.7% | REDUCED | 12.3% | 1Y +13.1% 5Y +68.9% · 7 models |
KYMERA THERAPEUTICS INC KYMERA THERAPEUTICS INC · COM · 501575104 | LONG | 378,163 | $43.4 million | 1.7% | INCREASED | — | 1Y — 5Y — |
RHYTHM PHARMACEUTICALS INC RHYTHM PHARMACEUTICALS INC · COM · 76243J105 | LONG | 381,128 | $42.3 million | 1.6% | INCREASED | — | 1Y — 5Y — |
DAMORA THERAPEUTICS INC DAMORA THERAPEUTICS INC · COM NEW · 36322Q206 | LONG | 1,620,377 | $42.1 million | 1.6% | INCREASED | — | 1Y — 5Y — |
ACADIA PHARMACEUTICALS INC ACADIA PHARMACEUTICALS INC · COM · 004225108 | LONG | 1,646,399 | $41.7 million | 1.6% | REDUCED | — | 1Y — 5Y — |
BRIGHTSPRING HEALTH SVCS INC BRIGHTSPRING HEALTH SVCS INC · COM · 10950A106 | LONG | 596,753 | $41.6 million | 1.6% | REDUCED | — | 1Y — 5Y — |
TRANSMEDICS GROUP INC TRANSMEDICS GROUP INC · COM · 89377M109 | LONG | 609,715 | $40.5 million | 1.6% | INCREASED | — | 1Y — 5Y — |
MBX BIOSCIENCES INC MBX BIOSCIENCES INC · COM · 55287L101 | LONG | 710,880 | $39.2 million | 1.5% | REDUCED | — | 1Y — 5Y — |
CLIMB BIO INC CLIMB BIO INC · COM · 28658R106 | LONG | 2,797,375 | $36.5 million | 1.4% | INCREASED | — | 1Y — 5Y — |
CAREDX INC CAREDX INC · COM · 14167L103 | LONG | 1,220,602 | $34.8 million | 1.3% | REDUCED | — | 1Y — 5Y — |
MAZE THERAPEUTICS INC MAZE THERAPEUTICS INC · COM · 578784100 | LONG | 1,140,040 | $34.0 million | 1.3% | NEWLY REPORTED | — | 1Y — 5Y — |
BRIGHT MINDS BIOSCIENCES INC BRIGHT MINDS BIOSCIENCES INC · COM NEW · 10919W405 | LONG | 483,822 | $34.0 million | 1.3% | REDUCED | — | 1Y — 5Y — |
ACADIA HEALTHCARE COMPANY IN ACADIA HEALTHCARE COMPANY IN · COM · 00404A109 | LONG | 1,141,477 | $33.7 million | 1.3% | INCREASED | — | 1Y — 5Y — |
NEKTAR THERAPEUTICS NEKTAR THERAPEUTICS · COM NEW · 640268306 | LONG | 473,617 | $33.1 million | 1.3% | INCREASED | — | 1Y — 5Y — |
CORVUS PHARMACEUTICALS INC CORVUS PHARMACEUTICALS INC · COM · 221015100 | LONG | 2,126,298 | $31.8 million | 1.2% | INCREASED | — | 1Y — 5Y — |
NURIX THERAPEUTICS INC NURIX THERAPEUTICS INC · COM · 67080M103 | LONG | 1,286,769 | $31.2 million | 1.2% | REDUCED | — | 1Y — 5Y — |
INSPIRE MED SYS INC INSPIRE MED SYS INC · COM · 457730109 | LONG | 677,570 | $30.2 million | 1.2% | UNCHANGED | — | 1Y — 5Y — |
AVALO THERAPEUTICS INC AVALO THERAPEUTICS INC · COM NEW · 05338F306 | LONG | 1,629,182 | $30.1 million | 1.2% | NEWLY REPORTED | — | 1Y — 5Y — |
ALAMAR BIOSCIENCES INC ALAMAR BIOSCIENCES INC · COMMON STOCK · 010911105 | LONG | 1,083,983 | $29.4 million | 1.1% | NEWLY REPORTED | — | 1Y — 5Y — |
DHR Danaher Corporation | LONG | 150,627 | $28.7 million | 1.1% | INCREASED | 13.6% | 1Y +12.0% 5Y +67.6% · 5 models |
ISRG INTUITIVE SURGICAL INC · COM NEW · 46120E602 | LONG | 70,137 | $27.9 million | 1.1% | REDUCED | — | 1Y +14.6% 5Y +83.4% · 5 models |
ORUKA THERAPEUTICS INC ORUKA THERAPEUTICS INC · COM · 687604108 | LONG | 278,164 | $26.5 million | 1.0% | NEWLY REPORTED | — | 1Y — 5Y — |
AVALYN PHARMACEUTICALS INC AVALYN PHARMACEUTICALS INC · COM SHS · 05348Y105 | LONG | 801,395 | $26.4 million | 1.0% | NEWLY REPORTED | — | 1Y — 5Y — |
AVEANNA HEALTHCARE HLDGS INC AVEANNA HEALTHCARE HLDGS INC · COM · 05356F105 | LONG | 3,065,106 | $26.3 million | 1.0% | INCREASED | — | 1Y — 5Y — |
BIOAGE LABS INC BIOAGE LABS INC · COM · 09077V100 | LONG | 1,033,129 | $25.3 million | 1.0% | REDUCED | — | 1Y — 5Y — |
BSX Boston Scientific | LONG | 587,567 | $25.1 million | 1.0% | INCREASED | — | 1Y — 5Y — |
VERA THERAPEUTICS INC VERA THERAPEUTICS INC · CL A · 92337R101 | LONG | 564,724 | $24.2 million | 0.9% | INCREASED | — | 1Y — 5Y — |
REPLIGEN CORP REPLIGEN CORP · COM · 759916109 | LONG | 177,100 | $24.2 million | 0.9% | INCREASED | — | 1Y — 5Y — |
ZURA BIO LTD ZURA BIO LTD · CLASS A ORD SHS · G9TY5A101 | LONG | 3,980,295 | $23.5 million | 0.9% | REDUCED | — | 1Y — 5Y — |
GUARDANT HEALTH INC GUARDANT HEALTH INC · COM · 40131M109 | LONG | 147,850 | $22.2 million | 0.9% | REDUCED | — | 1Y — 5Y — |
EVOLUS INC EVOLUS INC · COM · 30052C107 | LONG | 3,155,209 | $21.9 million | 0.8% | INCREASED | — | 1Y — 5Y — |
NTRA NATERA INC · COM · 632307104 | LONG | 79,500 | $21.6 million | 0.8% | REDUCED | — | 1Y — 5Y — |
ORTHOPEDIATRICS CORP ORTHOPEDIATRICS CORP · COM · 68752L100 | LONG | 1,100,370 | $21.1 million | 0.8% | UNCHANGED | — | 1Y — 5Y — |
ELEVANCE HEALTH INC FORMERLY ELEVANCE HEALTH INC FORMERLY · COM · 036752103 | LONG | 53,960 | $20.9 million | 0.8% | REDUCED | — | 1Y — 5Y — |
TECTONIC THERAPEUTIC INC TECTONIC THERAPEUTIC INC · COM · 878972108 | LONG | 596,900 | $20.5 million | 0.8% | REDUCED | — | 1Y — 5Y — |
DYNE THERAPEUTICS INC DYNE THERAPEUTICS INC · COM · 26818M108 | LONG | 921,598 | $20.5 million | 0.8% | REDUCED | — | 1Y — 5Y — |
NEOGENOMICS INC NEOGENOMICS INC · NOTE 0.250% 1/1 · 64049MAB6 | LONG | 18,011,000 | $16.9 million | — | NEWLY REPORTED | — | 1Y — 5Y — |
IMMUNOCORE HLDGS PLC IMMUNOCORE HLDGS PLC · ADS · 45258D105 | LONG | 521,327 | $16.6 million | — | NEWLY REPORTED | — | 1Y — 5Y — |
REPLIGEN CORP REPLIGEN CORP · NOTE 1.000%12/1 · 759916AD1 | LONG | 16,000,000 | $16.4 million | — | NEWLY REPORTED | — | 1Y — 5Y — |
ARGENX SE ARGENX SE · SPONSORED ADR · 04016X101 | LONG | 17,707 | $16.4 million | 0.6% | REDUCED | — | 1Y — 5Y — |
CELLDEX THERAPEUTICS INC NEW CELLDEX THERAPEUTICS INC NEW · COM NEW · 15117B202 | LONG | 436,646 | $16.2 million | 0.6% | REDUCED | — | 1Y — 5Y — |
OVID THERAPEUTICS INC OVID THERAPEUTICS INC · COM · 690469101 | LONG | 5,919,464 | $15.9 million | 0.6% | NEWLY REPORTED | — | 1Y — 5Y — |
MANNKIND CORP MANNKIND CORP · COM NEW · 56400P706 | LONG | 3,458,429 | $14.7 million | 0.6% | NEWLY REPORTED | — | 1Y — 5Y — |
UNIQURE NV UNIQURE NV · SHS · N90064101 | LONG | 301,652 | $13.9 million | 0.5% | NEWLY REPORTED | — | 1Y — 5Y — |
X4 PHARMACEUTICALS INC X4 PHARMACEUTICALS INC · COM NEW · 98420X202 | LONG | 2,922,754 | $13.6 million | 0.5% | REDUCED | — | 1Y — 5Y — |
ORIC PHARMACEUTICALS INC ORIC PHARMACEUTICALS INC · COM · 68622P109 | LONG | 1,214,540 | $13.2 million | 0.5% | INCREASED | — | 1Y — 5Y — |
KINIKSA PHARMACEUTICALS INTL KINIKSA PHARMACEUTICALS INTL · ORD SHS CL A · G52694109 | LONG | 183,822 | $11.8 million | 0.5% | REDUCED | — | 1Y — 5Y — |
OCULIS HOLDING AG OCULIS HOLDING AG · ORDINARY SHARES · H5870P102 | LONG | 834,183 | $11.6 million | 0.4% | NEWLY REPORTED | — | 1Y — 5Y — |
ACLARIS THERAPEUTICS INC ACLARIS THERAPEUTICS INC · COM · 00461U105 | LONG | 2,142,348 | $11.3 million | 0.4% | INCREASED | — | 1Y — 5Y — |
SEAPORT THERAPEUTICS INC SEAPORT THERAPEUTICS INC · COMMON STOCK · 81221K108 | LONG | 500,000 | $10.9 million | 0.4% | NEWLY REPORTED | — | 1Y — 5Y — |
VOR BIOPHARMA INC VOR BIOPHARMA INC · COM NEW · 929033207 | LONG | 573,104 | $10.6 million | 0.4% | INCREASED | — | 1Y — 5Y — |
SURROZEN INC SURROZEN INC · COM NEW · 86889P208 | LONG | 390,753 | $10.1 million | 0.4% | REDUCED | — | 1Y — 5Y — |
IMMUNIC INC IMMUNIC INC · COM NEW · 4525EP200 | LONG | 645,010 | $9.9 million | 0.4% | NEWLY REPORTED | — | 1Y — 5Y — |
HELIX ACQUISITION CORP III HELIX ACQUISITION CORP III · USD CL A ORD SHS · G4444S107 | LONG | 900,000 | $9.5 million | 0.4% | UNCHANGED | — | 1Y — 5Y — |
IONIS PHARMACEUTICALS INC IONIS PHARMACEUTICALS INC · COM · 462222100 | LONG | 116,762 | $9.3 million | 0.4% | REDUCED | — | 1Y — 5Y — |
QUEST DIAGNOSTICS INC QUEST DIAGNOSTICS INC · COM · 74834L100 | LONG | 43,200 | $9.2 million | 0.4% | NEWLY REPORTED | — | 1Y — 5Y — |
ADLAI NORTYE LTD ADLAI NORTYE LTD · SPONSORED ADS · 00704R109 | LONG | 795,214 | $9.1 million | 0.4% | NEWLY REPORTED | — | 1Y — 5Y — |
TENAX THERAPEUTICS INC TENAX THERAPEUTICS INC · COM NEW · 88032L605 | LONG | 584,412 | $8.5 million | 0.3% | NEWLY REPORTED | — | 1Y — 5Y — |
KARDIGAN INC KARDIGAN INC · COM · 485925101 | LONG | 300,000 | $7.2 million | 0.3% | NEWLY REPORTED | — | 1Y — 5Y — |
AMANAT ACQUISITION CORP AMANAT ACQUISITION CORP · CL A ORD · G0375M101 | LONG | 700,000 | $7.1 million | 0.3% | NEWLY REPORTED | — | 1Y — 5Y — |
HEMAB THERAPEUTICS HLDGS INC HEMAB THERAPEUTICS HLDGS INC · COM SHS · 423494103 | LONG | 160,000 | $5.9 million | 0.2% | NEWLY REPORTED | — | 1Y — 5Y — |
GH RESEARCH PLC GH RESEARCH PLC · ORDINARY SHARES · G3855L106 | LONG | 207,240 | $5.6 million | 0.2% | NEWLY REPORTED | — | 1Y — 5Y — |
WAT Waters Corporation | LONG | 14,040 | $5.3 million | 0.2% | NEWLY REPORTED | 11.2% | 1Y +11.8% 5Y +55.9% · 7 models |
RESEARCH ALLIANCE CORP III RESEARCH ALLIANCE CORP III · ORD SHS CL A · G75226103 | LONG | 400,000 | $4.3 million | 0.2% | NEWLY REPORTED | — | 1Y — 5Y — |
JATT II ACQUISITION CORP JATT II ACQUISITION CORP · ORD SHS · G50765109 | LONG | 250,000 | $2.8 million | 0.1% | NEWLY REPORTED | — | 1Y — 5Y — |
PULMONX CORP PULMONX CORP · COM · 745848101 | LONG | 752,541 | $978,303 | 0.0% | UNCHANGED | — | 1Y — 5Y — |
VYNE THERAPEUTICS INC VYNE THERAPEUTICS INC · COM · 92941V308 | LONG | 916,077 | $596,091 | 0.0% | UNCHANGED | — | 1Y — 5Y — |
CYCLERION THERAPEUTICS INC CYCLERION THERAPEUTICS INC · COM · 23255M204 | LONG | 156,890 | $531,857 | 0.0% | NEWLY REPORTED | — | 1Y — 5Y — |
Every filing event remains separate, including notices and amendments. Open a holdings date for the canonical portfolio through its latest filing, or an accession for the exact source event.
| Holdings date | Filed | Form | Processing | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | 13F-HR | VALIDATED | 0001420506-26-001823 |
| 2026-03-31 | 2026-05-15 | 13F-HR | VALIDATED | 0001420506-26-001145 |
| 2025-12-31 | 2026-02-17 | 13F-HR | VALIDATED | 0001420506-26-000586 |
| 2025-09-30 | 2025-11-14 | 13F-HR | VALIDATED | 0001420506-25-003410 |
| 2025-06-30 | 2025-08-14 | 13F-HR | VALIDATED | 0001420506-25-002183 |
| 2025-03-31 | 2025-05-15 | 13F-HR | VALIDATED | 0001420506-25-001293 |
| 2024-12-31 | 2025-02-14 | 13F-HR | QUARANTINED | 0001920938-25-000002 |
| 2024-09-30 | 2024-11-14 | 13F-HR | VALIDATED | 0001920938-24-000006 |
| 2024-06-30 | 2024-08-14 | 13F-HR | VALIDATED | 0001420506-24-001566 |
| 2024-03-31 | 2024-05-15 | 13F-HR | VALIDATED | 0001920938-24-000004 |
| 2023-12-31 | 2024-02-14 | 13F-HR | VALIDATED | 0001420506-24-000478 |
| 2023-09-30 | 2023-11-14 | 13F-HR | VALIDATED | 0001420506-23-002213 |
| 2023-06-30 | 2023-08-14 | 13F-HR | VALIDATED | 0001420506-23-001695 |
| 2023-03-31 | 2023-05-15 | 13F-HR | VALIDATED | 0000905148-23-000454 |
| 2022-12-31 | 2023-02-14 | 13F-HR | VALIDATED | 0001420506-23-000696 |